Multiple sclerosis (MS) has long been regarded as a chronic inflammatory disease of the
white matter that leads to demyelination and eventually to neurodegeneration. In the past …

Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system
characterized by focal or diffuse inflammation, demyelination, axonal loss and …

Intrathecal antibody production is a hallmark of multiple sclerosis and humoral immunity is
thought to play an important role in the inflammatory response and development of …

Objective To determine whether brain atrophy and lesion volumes predict subsequent 10
year clinical evolution in multiple sclerosis (MS). Design From eight MAGNIMS (MAGNetic …

Objective To determine gray matter (GM) atrophy rates in multiple sclerosis (MS) patients at
all stages of disease, and to identify predictors and clinical correlates of GM atrophy …

Objective To evaluate the extent to which treatment effect on brain atrophy is able to
mediate, at the trial level, the treatment effect on disability progression in relapsing–remitting …

Despite important advances in the treatment of multiple sclerosis (MS) over recent years, the
introduction of several disease-modifying therapies (DMTs), the burden of progressive …

During the past 10 years, the intense involvement of the grey matter of the CNS in the
pathology of multiple sclerosis has become evident. On gross inspection, demyelination in …

Multiple sclerosis (MS) has been classically regarded as a white matter disease. However,
recent histopathological studies have convincingly shown that grey matter regions are also …

Progressive multiple sclerosis is characterised clinically by the gradual accrual of disability
independent of relapses and can occur with disease onset (primary progressive) or can be …